DavidMRadinMD

Internal Medicine • Stamford, CT

Internal Medicine of Stamford, PC

Join to view full profile

Dr. Radin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Radin's full profile

Already have an account?

Office
144 Morgan St
Suite
Stamford, CT 06905
Phone+1 203-359-4888

Fax+1 203-359-6983

Summary

Dr. David Radin is an internist in Stamford, CT and is affiliated with Stamford Hospital. He received his medical degree from New York Medical College and has been in practice 230 years. He is experienced in preventive medicine, clinical research, and diagnostics.

Education & Training

New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Internal Medicine, 1990 - 1993
New York Medical CollegeClass of 1990
Massachusetts Institute of TechnologyBS, Chemistry, 1979 - 1983

Certifications & Licensure

CT State Medical License 1993 - 2025
NY State Medical License 1992 - 1999
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Top Doctors New York Metro Area Castle Connolly, 2020-2022
Top Doctors New York Magazine, 2021
Diabetes Recognition Program NCQA
PATIENT CENTERED MEDICAL HOME LEVEL 3 NCQA
Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Join now to see all

Clinical Trials

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. Start of enrollment: 2001 Sep 01
Completed
Phase 2
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain Start of enrollment: 2004 Feb 01
Terminated
Phase 3
Study of Milnacipran for the Treatment of Fibromyalgia Start of enrollment: 2006 Apr 01
Completed
Phase 3
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management Start of enrollment: 2006 Nov 01
Completed
Phase 3
A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome Start of enrollment: 2006 Feb 01
Completed
Phase 3
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions Start of enrollment: 2007 Nov 01
Completed
Phase 3
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults Start of enrollment: 2007 Nov 01
Completed
Phase 3
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus Start of enrollment: 2007 Dec 01
Completed
Phase 3
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management Start of enrollment: 2008 Jan 01
Completed
Phase 3
Tanezumab in Osteoarthritis Of The Hip Start of enrollment: 2008 Nov 17
Completed
Phase 3
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet Start of enrollment: 2007 Jun 01
Completed
Phase 2
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet Start of enrollment: 2007 Jun 01
Completed
Phase 2
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects Start of enrollment: 2008 Aug 01
Completed
Phase 2
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip Start of enrollment: 2009 Feb 12
Terminated
Phase 3
Extension Study Of Tanezumab In Osteoarthritis Start of enrollment: 2009 Feb 06
Terminated
Phase 3
Tanezumab In Osteoarthritis Of The Knee (2) Start of enrollment: 2009 May 05
Completed
Phase 3
A Study of Tanezumab in Adults With Chronic Low Back Pain Start of enrollment: 2009 Jun 15
Completed
Phase 2
Long Term Safety Study of Tanezumab in Chronic Low Back Pain Start of enrollment: 2009 Aug 20
Terminated
Phase 2
Tanezumab In Osteoarthritis Of The Hip Or Knee Start of enrollment: 2009 Oct 30
Terminated
Phase 3
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome Start of enrollment: 2010 Jan 22
Terminated
Phase 2
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia Start of enrollment: 2009 Nov 01
Completed
Phase 4
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain Start of enrollment: 2010 Mar 01
Completed
Phase 3
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study Start of enrollment: 2010 Mar 30
Terminated
Phase 3
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain Start of enrollment: 2010 May 01
Completed
Phase 3
Study of Fibromyalgia Treated With Milnacipran Start of enrollment: 2010 May 01
Completed
Phase 4
Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis Start of enrollment: 2010 Jun 15
Terminated
Phase 3
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain Start of enrollment: 2010 Sep 01
Completed
Phase 3
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults Start of enrollment: 2010 Oct 01
Completed
Phase 2
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Start of enrollment: 2011 Mar 01
Terminated
Phase 3
Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel Start of enrollment: 2011 Apr 01
Completed
Phase 3
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Start of enrollment: 2011 Mar 01
Completed
Phase 3
Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1% Start of enrollment: 2011 Sep 01
Completed
Phase 3
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term) Start of enrollment: 2012 Jan 01
Completed
Phase 3
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension Start of enrollment: 2012 Jan 01
Completed
Phase 3
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Start of enrollment: 2012 Jun 01
Terminated
Phase 1
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) Start of enrollment: 2012 Jun 01
Terminated
Phase 3
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects Start of enrollment: 2012 Aug 01
Completed
Phase 3
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Start of enrollment: 2012 Oct 01
Completed
Phase 3
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects Start of enrollment: 2012 Sep 01
Completed
Phase 3
Long-term Open-Label Safety Study to Evaluate EN3409 Start of enrollment: 2012 Dec 01
Completed
Phase 3
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation Start of enrollment: 2013 Apr 01
Terminated
Phase 3
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation Start of enrollment: 2013 Sep 01
Completed
Phase 3
Methylnaltrexone for Opioid Induced Constipation Start of enrollment: 2012 Jul 01
Terminated
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events Start of enrollment: 2013 Oct 01
Completed
Phase 3
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Start of enrollment: 2013 Oct 29
Terminated
Phase 3
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Start of enrollment: 2013 Oct 29
Terminated
Phase 3
A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee Start of enrollment: 2014 Jan 01
Completed
Phase 3
12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
Completed
Phase 3
Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain Start of enrollment: 2015 Mar 11
Completed
Phase 3
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain Start of enrollment: 2015 Apr 14
Completed
Phase 3
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee Start of enrollment: 2015 Jul 21
Completed
Phase 3
A Phase 3 Study of Tanezumab for Chronic Low Back Pain Start of enrollment: 2015 Aug 18
Completed
Phase 3
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement Start of enrollment: 2016 Aug 23
Completed
Phase 3
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee Start of enrollment: 2016 Jan 21
Completed
Phase 3
An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis Start of enrollment: 2016 Sep 19
Completed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) Start of enrollment: 2017 Apr 27
Active, not recruiting
Phase 3
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis Start of enrollment: 2017 Apr 24
Completed
Phase 2
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee Start of enrollment: 2017 Oct 30
Terminated
Phase 3
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip Start of enrollment: 2017 Oct 26
Completed
Phase 3
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension Start of enrollment: 2017 Oct 18
Completed
Phase 2, Phase 3
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) Start of enrollment: 2018 Sep 06
Completed
Phase 3
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Start of enrollment: 2018 Oct 09
Terminated
Phase 3
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2018 Jul 26
Completed
Phase 3
A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD) Start of enrollment: 2018 Aug 06
Active, not recruiting
Phase 2
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. Start of enrollment: 2018 Dec 17
Completed
Phase 2
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Start of enrollment: 2019 Apr 18
Completed
Phase 2
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis Start of enrollment: 2019 Apr 25
Active, not recruiting
Phase 4
Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis Start of enrollment: 2019 Jul 01
Completed
Phase 2
Open-label Extension Study Of RN624 Start of enrollment: 2006 Sep 15
Completed
Phase 2
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. Start of enrollment: 2021 Aug 31
Recruiting
Phase 3
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants Start of enrollment: 2021 Aug 25
Completed
Phase 2
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older Start of enrollment: 2022 Sep 12
Completed
Phase 3
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population Start of enrollment: 2021 Mar 08
Active, not recruiting
Phase 2
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2021 Jan 11
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

40 citations
Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
Leslie Tive, Alfonso E. Bello, David M. Radin, Thomas J. Schnitzer, Ha Nguyen
Journal of Pain Research. 2019-03-19
100 citations
Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Mark T. Brown, Frederick T. Murphy, David M. Radin, Isabelle Davignon, Michael D. Smith
Arthritis and Rheumatism. 2013-07-01
163 citations
Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Mark T. Brown, Frederick T. Murphy, David M. Radin, Isabelle Davignon, Michael D. Smith
The Journal of Pain. 2012-08-01

DavidMRadinMD

Dr. Radin is on Doximity

Summary

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.